Champions Oncology (CSBR) Total Debt to Capital

Champions Oncology dominates the tumor analysis segment due to low customer price sensitivity. The business relies on IT modeling and preclinical testing for pharmaceutical companies, ensuring a steady order flow. This chart shows the market price of the debt-to-equity ratio is 3.03, which complements the stability of the diagnostic expert team motivated by the development of a personalized approach to medicine.

This ratio compares total debt obligations to net assets, determining the business's degree of dependence on external financing and the stability of its financial framework. By analyzing the company's leverage history, an investor can assess the ability of Champions Oncology (CSBR) to withstand a revenue decline resulting from a reduction in preclinical orders amid high maintenance costs for tumor models.